Group 1: Core Insights - The Taizhou Bay Economic and Technological Development Zone's pharmaceutical park is a national pilot for pollution reduction and carbon emission control, implementing 20 green low-carbon technology transformation projects and achieving a carbon reduction of approximately 12,500 tons [1] - The park has established a complete industrial chain from intermediates to active pharmaceutical ingredients (APIs) and formulations, aiming to become a globally influential pharmaceutical innovation hub [2] - The transition from "pharmaceutical chemistry" to "pharmaceutical health" is a key path for industrial upgrading, with a focus on traditional pharmaceutical industries transforming into new materials and high-end formulations [2] Group 2: Technological Innovations - Huahai Pharmaceutical's Sichuan branch has achieved a 40% reduction in carbon emissions per unit output from 0.91 tons per 10,000 yuan in 2020 to 0.54 tons per 10,000 yuan in 2024, alongside significant waste reduction and economic benefits [3] - The company has implemented advanced solvent recovery technologies to improve energy efficiency and reduce steam and electricity consumption by 30% and 17% respectively [3] - A unique evaluation index for pollution reduction and carbon emission control in the pharmaceutical industry has been established, reflecting the levels of "pollution reduction," "carbon reduction," and "efficiency increase" [3] Group 3: Digital Empowerment - The Taizhou Bay Economic and Technological Development Zone has invested 100 million yuan in a "smart park" regulatory platform, integrating AI and big data for environmental management [4] - The park has developed a comprehensive ecological monitoring network that covers environmental quality, pollution sources, and ecological conditions [5] - The park has been recognized as a national pilot for innovative collaborative pollution reduction and carbon emission control, and has achieved the status of a "zero direct discharge" industrial park in Zhejiang Province [5]

Group 1: Company Overview - Company Name: Shandong Boyuan Pharmaceutical Chemical Co., Ltd. [1] - Stock Code: 301617 [1] - Stock Abbreviation: Boyuan Shares [1] Group 2: Investor Relations Activity - Activity Type: Online collective reception day for listed companies in Shandong [2] - Date of Activity: May 15, 2025 [2] - Time of Activity: 15:00 - 16:30 [2] - Location: P5W Investor Relations Interactive Platform [2] Group 3: Key Personnel - Chairman: Li Chenglin [2] - Vice Chairman and General Manager: Yu Guoqing [2] - Vice General Manager and Board Secretary: Zhang Shanggang [2] - Chief Financial Officer: Sun Teng [2] Group 4: Financial Performance - 2024 Revenue: 132,787.79 million yuan, a year-on-year increase of 29.53% [2] - 2024 Net Profit: 21,312.58 million yuan, a year-on-year increase of 17.04% [2] Group 5: Investor Inquiries - Inquiry about overall performance in 2024 compared to 2023 [2] - Company response regarding performance changes [2]